If you have been reading about Ac-SDKP and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-28. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
== Medical uses == Liraglutide is an anti-diabetic medication used for the treatment of type 2 diabetes or obesity. Liraglutide (Victoza) is indicated as an adjunct to diet and exercise to improve glycemic control in people aged ten years of age and older with type 2 diabetes; and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Liraglutide (Saxenda) is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in people aged twelve years of age and older with body weight greater than 60 kilograms (130 lb) and obesity; and in adults with overweight in the presence of at least one weight-related comorbid condition.
== Risks == There are over 250 toxins and carcinogens in cigarette smoke. The risks of developing lung cancer, brain tumors, and acute myeloid leukemia and the incidence of heart disease and benign respiratory diseases increase with the inhalation of sidestream smoke. Additionally, the chance of developing breast cancer and cervical cancer also increases with the inhalation of sidestream smoke. Evidence has shown that sidestream smoke may be more harmful, per gram, than mainstream smoke. However, sidesmoke is inhaled in far lesser amounts than mainstream smoke in people who smoke tobacco. The relative risk of cardiovascular disease is 1.2–1.3 with exposure to sidestream smoke due to the cyanide present in the smoke. There is also evidence that sidestream smoke causes negative effects in children, both behaviorally and cognitively. One study found that higher levels of cotinine in children were correlated with a decreased ability to perform in reading and math. Factors such as age, gender and different occupations put a person at risk for bladder cancer - smoking is the only other known risk. 4-aminobiphenyl (4-ABP) is an integral component in tobacco smoke, as well as a risk factor for bladder cancer. Sidestream smoke puts individuals at an increased risk of bladder cancer because the 4-ABP concentrations are over ten times that of mainstream smoke.
=== Translation start sites === Using a method developed by Hunt, Shine and Dalgarno showed that the nucleotide tract at the 3' end of E. coli 16S ribosomal RNA (rRNA) (that is, the end where translation begins) is pyrimidine-rich and has the specific sequence 5'-YACCUCCUUA-3'. They proposed that these ribosomal nucleotides recognize the complementary purine-rich sequence 5'-AGGAGGU-3', which is found upstream of the start codon AUG in a number of mRNAs found in viruses that affect E. coli. Many studies have confirmed that base pairing between the Shine–Dalgarno sequence in mRNA and the 3' end of 16S rRNA is of prime importance for initiation of translation by bacterial ribosomes. Given the complementary relationship between rRNA and the Shine–Dalgarno sequence in mRNA, it was proposed that the sequence at the 3'-end of the rRNA determines the capacity of the prokaryotic ribosome to translate a particular gene in an mRNA. Base pairing between the 3'-end of the rRNA and the Shine–Dalgarno sequence in mRNA is a mechanism by which the cell can distinguish between initiator AUGs and internal and/or out-of-frame AUG sequences. The degree of base pairing also plays a role in determining the rate of initiation at different AUG initiator codons.
Sources: en.wikipedia.org
== Electronic integration == Integration of microfluidic platforms and electronic components have the potential to generate micro total analysis systems (μTAS), which are devices that include and automate all essential steps for sample preparation and analysis. Paper electronics rely on functional structures like conductors to be fabricated on the surface of paper, but paper-based microfluidics rely on channels and barriers to be fabricated inside the substrate. This incompatibility led to a majority of μTAS being developed using external electrodes contacted with the paper channels. However, in 2009, screen-printed electrodes were integrated into a paper-based microfluidic device to create a biosensor for glucose, lactate, and uric acid. This first report of electronic integration for paper-based microfluidics illustrated how this can improve the design of μTAS at a low cost. Since then, a variety of electrode fabrication techniques have been developed, including screen printing, inkjet printing, metal sputter deposition, pencil drawing, laser-induced pyrolysis and external electrodes to create a network of conductive traces.
=== Jonah Atterbury === Jonah Atterbury (Kal Penn) is the co-founder and CEO of Tender, which he started with his college friend Whitney Halberstram. Once an ambitious business school graduate, Jonah has since devolved into an irresponsible and inattentive CEO, addicted to partying, drugs, and pornography, and frequently showing up intoxicated to the office. He clashes with Whitney over the latter's desire to pivot Tender away from lucrative "alternative merchants" like porn and gambling and towards banking. Whitney and the Tender board soon use behavioral clauses in Jonah's contract to remove him as CEO, citing his inappropriate behavior, poor hygiene, and misuse of company funds; Whitney takes over in the interim. Jonah is later contacted by Sweetpea Golightly, who is investigating Tender's shady finances as part of a short; a vengeful Jonah, who is suing Whitney for defamation, emails Sweetpea a trove of subpoenaed internal Tender emails that she uses to uncover a connection to Accra. After Tender's stock plummets following revelations of its fraud, Whitney attempts to contact Jonah, who rebuffs him.
In response to public pressure felt from policies de-emphasizing bottle- and formula-feeding, efforts have arisen to support mothers experiencing physiologic or other difficulties in breastfeeding, and sites include individual views that attempt to weaken the scientific case of the AAP policy; a book of the personal experiences and views of one mother committed to bottle/formula feeding, Bottled Up, by Suzanne Barston, has appeared. In 2007, a group of 38 researchers examined 700 studies into the use of the chemical compound Bisphenol A in plastics manufacturing, and warned that very low levels of exposure to the chemical can potentially pose adverse health effects, especially to a developing fetus. In 2024, multiple baby bottle companies, including Nuk, Tommee Tippee, and Dr. Brown's, were involved in a class action lawsuit for their bottles leaching microplastics when heated.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.